-
Something wrong with this record ?
Novel neuroprotective 5,6-dihydropyrido[2',1':2,3]imidazo[4,5-c]quinoline derivatives acting through cholinesterase inhibition and CB2 signaling modulation
S. Jena, G. Gonzalez, D. Vítek, M. Kvasnicová, Š. Štěpánková, M. Strnad, J. Voller, K. Chanda
Language English Country France
Document type Journal Article
- MeSH
- Quinolines * pharmacology chemistry chemical synthesis MeSH
- Cholinesterase Inhibitors * pharmacology chemistry chemical synthesis MeSH
- Humans MeSH
- Molecular Structure MeSH
- Cell Line, Tumor MeSH
- Neuroprotective Agents * pharmacology chemistry chemical synthesis MeSH
- Receptor, Cannabinoid, CB2 * metabolism antagonists & inhibitors MeSH
- Signal Transduction * drug effects MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
A novel group of 5,6-dihydropyrido [2',1':2,3]imidazo [4,5-c]quinolines was prepared via a microwave assisted one-pot telescopic approach. The synthetic sequence involves the formation of an amine precursor of imidazo [1,2-a]pyridine via condensation and reduction under microwave irradiation. Subsequently, the Pictet-Spengler cyclisation reaction occurs with ketones (cyclic or acyclic) to obtain substituted 5,6-dihydropyrido [2',1':2,3]imidazo [4,5-c]quinolines in excellent yields. The compounds were tested as neuroprotective agents. Observed protection of neuron-like cells, SH-SY5Y differentiated with ATRA, in Parkinson's and Huntington's disease models inspired further mechanistic studies of protective activity against damage induced by 1-methyl-4-phenylpyridinium (MPP+), a compound causing Parkinson's disease. The novel compounds exhibit similar or higher potency than ebselen, an established drug with antioxidant activity, in the cells against MPP + -induced total cellular superoxide production and cell death. However, they exhibit a significantly higher capacity to reduce mitochondrial superoxide and preserve mitochondrial membrane potential. We also observed marked differences between a selected derivative and ebselen in terms of normalizing MPP + -induced phosphorylation of Akt and ERK1/2. The cytoprotective activity was abrogated when signaling through cannabinoid receptor CB2 was blocked. The compounds also inhibit both acetylcholine and butyrylcholine esterases. Overall the data show that novel 5,6-dihydropyrido [2',1':2,3]imidazo [4,5-c]quinoline have a broad cytoprotective activity which is mediated by several mechanisms including mitoprotection.
Department of Chemistry Rabindranath Tagore University Hojai Assam 782435 India
Department of Neurology University Hospital in Olomouc 1 P Pavlova 6 77520 Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018724
- 003
- CZ-PrNML
- 005
- 20241024111232.0
- 007
- ta
- 008
- 241015e20240617fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2024.116592 $2 doi
- 035 __
- $a (PubMed)39013357
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Jena, Sushovan $u Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India
- 245 10
- $a Novel neuroprotective 5,6-dihydropyrido[2',1':2,3]imidazo[4,5-c]quinoline derivatives acting through cholinesterase inhibition and CB2 signaling modulation / $c S. Jena, G. Gonzalez, D. Vítek, M. Kvasnicová, Š. Štěpánková, M. Strnad, J. Voller, K. Chanda
- 520 9_
- $a A novel group of 5,6-dihydropyrido [2',1':2,3]imidazo [4,5-c]quinolines was prepared via a microwave assisted one-pot telescopic approach. The synthetic sequence involves the formation of an amine precursor of imidazo [1,2-a]pyridine via condensation and reduction under microwave irradiation. Subsequently, the Pictet-Spengler cyclisation reaction occurs with ketones (cyclic or acyclic) to obtain substituted 5,6-dihydropyrido [2',1':2,3]imidazo [4,5-c]quinolines in excellent yields. The compounds were tested as neuroprotective agents. Observed protection of neuron-like cells, SH-SY5Y differentiated with ATRA, in Parkinson's and Huntington's disease models inspired further mechanistic studies of protective activity against damage induced by 1-methyl-4-phenylpyridinium (MPP+), a compound causing Parkinson's disease. The novel compounds exhibit similar or higher potency than ebselen, an established drug with antioxidant activity, in the cells against MPP + -induced total cellular superoxide production and cell death. However, they exhibit a significantly higher capacity to reduce mitochondrial superoxide and preserve mitochondrial membrane potential. We also observed marked differences between a selected derivative and ebselen in terms of normalizing MPP + -induced phosphorylation of Akt and ERK1/2. The cytoprotective activity was abrogated when signaling through cannabinoid receptor CB2 was blocked. The compounds also inhibit both acetylcholine and butyrylcholine esterases. Overall the data show that novel 5,6-dihydropyrido [2',1':2,3]imidazo [4,5-c]quinoline have a broad cytoprotective activity which is mediated by several mechanisms including mitoprotection.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a neuroprotektivní látky $x farmakologie $x chemie $x chemická syntéza $7 D018696
- 650 12
- $a cholinesterasové inhibitory $x farmakologie $x chemie $x chemická syntéza $7 D002800
- 650 12
- $a chinoliny $x farmakologie $x chemie $x chemická syntéza $7 D011804
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 12
- $a signální transdukce $x účinky léků $7 D015398
- 650 12
- $a receptor kanabinoidní CB2 $x metabolismus $x antagonisté a inhibitory $7 D043885
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a zvířata $7 D000818
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gonzalez, Gabriel $u Department of Experimental Biology, Palacky University Olomouc, Faculty of Science, Šlechtitelů 27, 78371, Olomouc, Czech Republic; Department of Neurology, University Hospital in Olomouc, I. P. Pavlova 6, 77520, Olomouc, Czech Republic
- 700 1_
- $a Vítek, Dominik $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77515, Olomouc, Czech Republic
- 700 1_
- $a Kvasnicová, Marie $u Department of Experimental Biology, Palacky University Olomouc, Faculty of Science, Šlechtitelů 27, 78371, Olomouc, Czech Republic; Laboratory of Growth Regulators, Faculty of Science, Palacký University Olomouc, and Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, CZ-78371, Olomouc, Czech Republic
- 700 1_
- $a Štěpánková, Šárka $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 53210, Pardubice, Czech Republic
- 700 1_
- $a Strnad, Miroslav $u Laboratory of Growth Regulators, Faculty of Science, Palacký University Olomouc, and Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, CZ-78371, Olomouc, Czech Republic
- 700 1_
- $a Voller, Jiří $u Department of Experimental Biology, Palacky University Olomouc, Faculty of Science, Šlechtitelů 27, 78371, Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77515, Olomouc, Czech Republic. Electronic address: jiri.voller@upol.cz
- 700 1_
- $a Chanda, Kaushik $u Department of Chemistry, Rabindranath Tagore University, Hojai, Assam, 782435, India. Electronic address: chandakaushik1@gmail.com
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 276 (20240617), s. 116592
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39013357 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111226 $b ABA008
- 999 __
- $a ok $b bmc $g 2201535 $s 1230697
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 276 $c - $d 116592 $e 20240617 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20241015